National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Bendamustine (Levact®) for the treatment of Chronic Lymphocytic Leukaemia (CLL)

Rapid Review

Commenced Completed Outcome
March 2011 21/03/2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
08/03/2012  20/11/2012 Reimbursement recommended

 The NCPE  recommends reimbursement of bendamustine (Levact®) for patients unable to tolerate fludarabine/cyclophosphamide.

Summary Bendamustine